openPR Logo
Press release

Campylobacter Infections Market is expected to reach USD 4.9 billion by 2034

09-11-2025 01:47 PM CET | Health & Medicine

Press release from: Exactitude Consultancy

Campylobacter Infections

Campylobacter Infections

Campylobacter infections, primarily caused by Campylobacter jejuni and Campylobacter coli, are among the leading causes of bacterial gastroenteritis worldwide. Transmission occurs mainly through contaminated food and water, especially undercooked poultry, unpasteurized milk, and untreated water sources. Symptoms include diarrhea (sometimes bloody), abdominal pain, fever, and in rare cases, severe complications such as Guillain-Barré syndrome.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71763

Despite being self-limiting in many cases, severe infections require antibiotic treatment. The market is shaped by rising global incidence of foodborne diseases, increasing adoption of molecular diagnostics, and growing concern over antimicrobial resistance (AMR).

Market Overview
• Market Size (2024): USD 2.7 billion
• Forecast (2034): USD 4.9 billion
• CAGR (2025-2034): 6.3%

Growth is fueled by the increasing burden of foodborne illness, wider diagnostic adoption, and AMR-focused research.

Key Highlights:
• Campylobacter causes ~96 million cases annually worldwide.
• Antibiotic resistance (macrolides, fluoroquinolones) is a major treatment challenge.
• Molecular PCR panels accelerating diagnosis compared to stool culture.
• Food safety initiatives and surveillance programs driving awareness.

Segmentation Analysis
By Product Type:
• Antibiotics
o Macrolides (Azithromycin, Erythromycin - first-line therapies)
o Fluoroquinolones (Ciprofloxacin, Levofloxacin - limited due to resistance)
o Tetracyclines (Doxycycline)
o Carbapenems (for severe resistant cases)

• Diagnostics
o Stool Culture (traditional)
o PCR-Based Molecular Panels
o Rapid Antigen Tests

• Supportive Care
o Rehydration Solutions
o Electrolyte Therapy
o Probiotics (adjunct therapy)

By Platform:
• Pharmaceuticals (antibiotics)
• Diagnostics
• Supportive Care

By Technology:
• Multiplex PCR Respiratory & Enteric Panels
• Whole-Genome Sequencing for AMR Surveillance
• AI-Based Outbreak Tracking

By End Use:
• Hospitals & Clinics
• Diagnostic Laboratories
• Public Health Agencies
• Home Care (rehydration, OTC solutions)

By Application:
• Pediatric Campylobacter Infections
• Adult Infections
• Severe/Complicated Infections (Guillain-Barré, Bacteremia)
• Clinical Research

Segmentation Summary:
Antibiotics dominate in severe infections, but diagnostics and supportive care are expanding as key growth areas. Rapid molecular panels are replacing culture as the gold standard for detection.

Explore Full Report here: https://exactitudeconsultancy.com/reports/71763/campylobacter-infections-market

Regional Analysis
North America
• ~35% share in 2024.
• High diagnostic adoption, strong surveillance by CDC and FDA.
• Rising resistance prompting AMR-focused research.
Europe
• ~30% share.
• EFSA surveillance highlighting Campylobacter as the most common foodborne pathogen.
• Strong regulatory focus on food safety and poultry industry.
Asia-Pacific
• Fastest-growing region with CAGR of ~7.2%.
• High prevalence due to food safety challenges in India, China, and Southeast Asia.
• Expanding diagnostic capacity in urban centers.
Middle East & Africa
• Significant prevalence due to limited sanitation and food safety infrastructure.
• Underdiagnosis common, though outbreak reporting is improving.
Latin America
• Brazil and Mexico lead growth.
• Increasing adoption of PCR-based diagnostics in urban hospitals.
Regional Summary:
North America and Europe dominate due to strong food safety regulations and diagnostics, while Asia-Pacific grows fastest due to high disease burden and improving healthcare systems.

Market Dynamics
Key Growth Drivers:
• Rising global incidence of foodborne illnesses.
• Expanding adoption of PCR-based molecular diagnostics.
• Growing government food safety initiatives and surveillance.
• Increased awareness of long-term complications (e.g., Guillain-Barré syndrome).

Key Challenges:
• Rising antibiotic resistance in Campylobacter strains.
• Underdiagnosis in rural and low-income regions.
• Limited treatment options beyond macrolides.
• High costs of advanced diagnostic panels.

Latest Trends:
• Whole-genome sequencing for outbreak tracing and AMR monitoring.
• Development of probiotics and microbiome-based adjunct therapies.
• AI-driven outbreak prediction models.
• Stronger poultry industry regulations to reduce contamination risk.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71763

Competitor Analysis
Major Players in the Market:
• Pfizer Inc.
• GlaxoSmithKline plc
• Novartis AG
• Sanofi S.A.
• Johnson & Johnson
• Abbott Laboratories (diagnostics)
• Roche Diagnostics
• BioMérieux SA (multiplex PCR panels)
• Thermo Fisher Scientific Inc.
• Danone S.A. (probiotic products)

Competitive Summary:
Pfizer, GSK, and Novartis lead in antibiotics, while Roche, Abbott, BioMérieux, and Thermo Fisher dominate diagnostics. Danone and other probiotic companies are entering supportive therapy markets. Competition focuses on antibiotic resistance, molecular diagnostics, and preventive strategies.

Conclusion
The Campylobacter Infections Market, valued at USD 2.7 billion in 2024, is projected to reach USD 4.9 billion by 2034, growing at a CAGR of 6.3%. Rising foodborne illness, improved diagnostics, and AMR-focused research will continue to shape the market.

Key Takeaways:
• Antibiotics remain key, but resistance is a growing challenge.
• North America and Europe dominate, while Asia-Pacific grows fastest.
• Diagnostics and surveillance are expanding to improve outbreak control.
• Probiotics and microbiome therapies represent new supportive care opportunities.

The next decade will redefine Campylobacter management through precision diagnostics, AMR-driven antibiotic strategies, and food safety innovation, creating strong opportunities for pharmaceutical, diagnostic, and food industry players.

This report is also available in the following languages : Japanese (カンピロバクター感染症市場), Korean (캄필로박터 감염 시장), Chinese (弯曲杆菌感染市场), French (Marché des infections à Campylobacter), German (Markt für Campylobacter-Infektionen), and Italian (Mercato delle infezioni da Campylobacter), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71763/campylobacter-infections-market#request-a-sample

Our More Reports:

Conjugation and Labeling Services Market
https://exactitudeconsultancy.com/reports/72423/conjugation-and-labeling-services-market

Nanoparticle Formulation Market
https://exactitudeconsultancy.com/reports/72422/nanoparticle-formulation-market

Allogeneic Cell Therapy Market
https://exactitudeconsultancy.com/reports/72421/allogeneic-cell-therapy-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Campylobacter Infections Market is expected to reach USD 4.9 billion by 2034 here

News-ID: 4179486 • Views:

More Releases from Exactitude Consultancy

Cancer Therapeutics Market to Reach USD 441.8 Billion by 2034, Growing at 7.2% CAGR; North America Leads
Cancer Therapeutics Market to Reach USD 441.8 Billion by 2034, Growing at 7.2% C …
Introduction Cancer continues to be one of the most formidable healthcare challenges worldwide, accounting for millions of deaths each year and placing immense strain on patients, families, and healthcare systems. Advances in oncology research over the past two decades have fundamentally reshaped the treatment landscape, moving beyond chemotherapy and radiation into a new era defined by immunotherapy, targeted therapies, and precision medicine. The global cancer therapeutics market today encompasses a wide spectrum
Cancer Therapeutics Market is expected to reach USD 441.8 billion by 2034
Cancer Therapeutics Market is expected to reach USD 441.8 billion by 2034
Cancer continues to be one of the most formidable healthcare challenges worldwide, accounting for millions of deaths each year and placing immense strain on patients, families, and healthcare systems. Advances in oncology research over the past two decades have fundamentally reshaped the treatment landscape, moving beyond chemotherapy and radiation into a new era defined by immunotherapy, targeted therapies, and precision medicine. The global cancer therapeutics market today encompasses a wide spectrum
Oral Proteins and Peptides Market to Reach USD 15.6 Billion by 2034
Oral Proteins and Peptides Market to Reach USD 15.6 Billion by 2034
Proteins and peptides represent one of the most promising classes of therapeutic agents, offering highly specific mechanisms of action that enable targeted treatment of diseases ranging from diabetes and cancer to autoimmune and metabolic disorders. Traditionally, however, these biologics have been limited by their delivery routes-primarily injectables-due to their poor stability and absorption in the gastrointestinal tract. In recent years, breakthroughs in oral protein and peptide drug delivery technologies have begun
Chronic Pain Treatment Market to Reach USD 144.2 Billion by 2034,
Chronic Pain Treatment Market to Reach USD 144.2 Billion by 2034,
Introduction Chronic pain, defined as pain persisting for more than three months, is one of the most significant healthcare challenges worldwide. It affects hundreds of millions of people globally, impairing quality of life, reducing productivity, and contributing to high healthcare costs. Conditions such as arthritis, neuropathic pain, cancer-related pain, and lower back disorders are among the most common causes of long-term pain. As awareness grows about the scale of the problem, healthcare

All 5 Releases


More Releases for Campylobacter

Campylobacter Test Kit Market Future Business Scope Analysis Report, Marketing S …
"The Campylobacter test kit market is projected to reach a value of approximately $600 million in 2024, driven by heightened food safety standards and increasing consumer awareness regarding foodborne illnesses. The market is expected to exhibit robust growth, with an anticipated compound annual growth rate (CAGR) of 6.5% from 2025 to 2034, potentially reaching around $1.1 billion by the end of the forecast period." Exactitude Consultancy., Ltd. released a research report
Campylobacter Infections Market Outlook Report 2032 | Campylobacter Infections M …
DelveInsight's "Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Campylobacter Infections, historical and forecasted epidemiology as well as the Campylobacter Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Campylobacter Infections market report provides current treatment practices, emerging drugs, Campylobacter Infections market share of the individual therapies, and current and forecasted Campylobacter Infections market size
Campylobacter Infections Market to Witness Growth by 2032, Estimates DelveInsigh …
DelveInsight's "Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Campylobacter Infections, historical and forecasted epidemiology as well as the Campylobacter Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Campylobacter Infections market report provides current treatment practices, emerging drugs, Campylobacter Infections market share of the individual therapies, and current and forecasted Campylobacter Infections market size
Campylobacter Infections Market to Witness Growth by 2032, Estimates DelveInsigh …
DelveInsight's "Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Campylobacter Infections, historical and forecasted epidemiology as well as the Campylobacter Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Campylobacter Infections market report provides current treatment practices, emerging drugs, Campylobacter Infections market share of the individual therapies, and current and forecasted Campylobacter Infections market size
Campylobacter Infections Market to Witness Growth by 2032, Estimates DelveInsigh …
DelveInsight's "Campylobacter Infections Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Campylobacter Infections, historical and forecasted epidemiology as well as the Campylobacter Infections market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Campylobacter Infections market report provides current treatment practices, emerging drugs, Campylobacter Infections market share of the individual therapies, and current and forecasted Campylobacter Infections market size
Campylobacter Diagnostics Market to See Incredible Growth During 2025
Campylobacter infection is an abnormality observed in the digestive system caused by campylobacter bacteria. The most common sources of campylobacter infection are unpasteurized milk, raw poultry, or uncooked vegetables. Major symptoms of campylobacter infection include diarrhea, blood and mucus in stool, malaise, severe abdominal pain, nausea, fever, vomiting, and headache. On average, campylobacter infection lasts from two to 10 days. Campylobacter infection is diagnosed through laboratory tests of stool, body